Today, the VP, Clinical Research of Cryolife (CRY), Scott Capps, sold shares of CRY for $57.1K.
Following Scott Capps’ last CRY Sell transaction on December 02, 2013, the stock climbed by 18.0%. In addition to Scott Capps, 5 other CRY executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $67.51 million and GAAP net loss of $295K. In comparison, last year the company earned revenue of $61.95 million and had a GAAP net loss of $3.82 million. Currently, Cryolife has an average volume of 313.2K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $33.50, reflecting a 16.5% upside.
The insider sentiment on Cryolife has been negative according to 95 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the Medical Devices, and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products; On-X products; CardioGenesis cardiac laser therapy; PerClot; and PhotoFix.
